The management of refractory Crohn's disease
Open Access
- 31 May 2002
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 16, 40-47
- https://doi.org/10.1046/j.1365-2036.16.s4.6.x
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Maintenance infliximab (Remicade) is safe, effective and steroid-sparing in Crohn's disease: Preliminary results from the accent i trialGastroenterology, 2001
- Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitisGastroenterology, 1999
- Clinical pattern of corticosteroid dependent Crohnʼs diseaseEuropean Journal of Gastroenterology & Hepatology, 1998
- Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)Gastroenterology, 1995
- Tumour-necrosis-factor antibody treatment in Crohn's diseaseThe Lancet, 1993
- Two TNF receptorsImmunology Today, 1992
- The mechanism for glucocorticoid-resistance in a rat hepatoma cell variant that contains functional glucocorticoid receptorThe Journal of Steroid Biochemistry and Molecular Biology, 1991
- A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contactCell, 1990
- Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestineClinical and Experimental Immunology, 1990
- Treatment of Crohn's Disease with 6-MercaptopurineNew England Journal of Medicine, 1980